Current application status and structure–activity relationship of selective and non-selective JAK inhibitors in diseases
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference59 articles.
1. Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus;Huo;J. Inflamm. Res.,2023
2. A Comprehensive Overview of Globally Approved JAK Inhibitors;Shawky;Pharmaceutics,2022
3. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders;Roskoski;Pharmacol. Res.,2022
4. The Janus kinase (JAK) FERM and SH2 domains: Bringing specificity to JAK–receptor interactions;Ferrao;Front. Endocrinol.,2017
5. The role of JAK/STAT signaling pathway and its inhibitors in diseases;Xin;Int. Immunopharmacol.,2020
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Medicinal chemistry perspective of JAK inhibitors: synthesis, biological profile, selectivity, and structure activity relationship;Molecular Diversity;2024-01-18
2. Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy;Frontiers in Pharmacology;2024-01-03
3. The efficacy and immunological effects of upadacitinib in the treatment of moderate-to-severe Chinese atopic dermatitis patients;International Immunopharmacology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3